Skip to main content
logo
TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
114.00
+4.80 (4.40%)
At close: Apr 10, 2026, 4:00 PM EDT
112.47
-1.53 (-1.34%)
Pre-market: Apr 13, 2026, 4:34 AM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
United States Lung Revenue
13.44M15.76M
United States Lung Revenue Growth
-14.67%49.36%
United States Heart Revenue
111.84M96.66M
United States Heart Revenue Growth
15.70%63.61%
United States Liver Revenue
459.42M309.46M
United States Liver Revenue Growth
48.46%103.97%
United States OCS Transplant Revenue
584.70M421.88M
United States OCS Transplant Revenue Growth
38.59%90.60%
All Other Countries Lung Revenue
1.42M1.93M
All Other Countries Lung Revenue Growth
-26.38%51.41%
All Other Countries Heart Revenue
14.17M13.20M
All Other Countries Heart Revenue Growth
7.36%-5.81%
All Other Countries Liver Revenue
1.11M158.00K
All Other Countries Liver Revenue Growth
604.43%51.92%
All Other Countries OCS Transplant Revenue
16.70M15.28M
All Other Countries OCS Transplant Revenue Growth
9.28%-0.69%
Total OCS Transplant Revenue
601.40M437.16M
Total OCS Transplant Revenue Growth
37.57%84.66%
Other Service Revenue
4.10M4.38M
Other Service Revenue Growth
-6.42%-10.43%
Revenue (Total)
605.49M441.54M
Revenue (Total) Growth
37.13%82.74%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Product Revenue
372.40M273.87M
Net Product Revenue Growth
35.98%55.55%
Service Revenue
233.09M167.67M
Service Revenue Growth
39.02%155.78%
Revenue (Total)
605.49M441.54M
Revenue (Total) Growth
37.13%82.74%
Updated Dec 31, 2025. Data Source: Fiscal.ai.